Pharmacotherapy Original research| Volume 34, ISSUE 8, P1705-1719, August 2012

I-COMBINE Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled With Amlodipine 5 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded–End Point Evaluation Study

  • Guillaume Bobrie
    Address correspondence to: Guillaume Bobrie, MD, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75908 PARIS cedex 15, France
    Department of Hypertension, Hôpital Européen Georges Pompidou, Paris, France
    Search for articles by this author
  • I-COMBINE Study Investigators
    Author Footnotes
    ⁎ Members of the I-COMBINE Study Investigators are listed in the Acknowledgments.
  • Author Footnotes
    ⁎ Members of the I-COMBINE Study Investigators are listed in the Acknowledgments.



      Hypertension guidelines recommend the use of 2 agents with synergistic action when >1 agent is needed to achieve blood pressure goals. Newer antihypertensive treatment combinations include fixed-dose combinations of an angiotensin receptor blocker and a calcium channel blocker.


      The I-COMBINE study aimed to determine whether the antihypertensive efficacy of the fixed-dose combination irbesartan 150 mg/amlodipine 5 mg (I150/A5) was superior to that of amlodipine 5 mg (A5) monotherapy in lowering home systolic blood pressure (HSBP) after 5 weeks' treatment.


      The I-COMBINE study was a 10-week, multicenter, Phase III, prospective, randomized, parallel-group, open-label with blinded–endpoint study. The main inclusion criterion was essential uncontrolled hypertension (SBP ≥145 mm Hg at office, after at least 4 weeks of A5 monotherapy administered once daily). Patients continued to receive A5 for 7 to 10 days and were randomized to either monotherapy with A5 for 5 weeks then amlodipine 10 mg (A10) for the next 5 weeks or to a fixed-dose combination therapy (I150/A5 then I150/A10). Safety profile was assessed by recording adverse events reported by patients or observed by the investigator.


      Following enrollment, 290 patients were randomized to treatment, and 287 (mean [SD] age, 57.3 [11.2] years; 48% male) were included in the intention-to-treat analysis: 144 patients treated with I150/A5 then I150/A10, and 143 patients treated with A5 then A10. At randomization, mean HSBP was similar in both groups: 148.5 (10.3) mm Hg in the I150/A5 group and 149.2 (9.7) mm Hg in the A5 group. At week 5, the adjusted mean difference in HSBP between groups was –6.2 (1.0) mm Hg (P < 0.001). The proportion of controlled patients (mean home blood pressure <135 and 85 mm Hg) was significantly higher in the I150/A5 group than in the A5 group (P < 0.001). Treatment-emergent adverse events were experienced by 13.8% of I150/A5-treated patients and 11.9% of A5-treated patients during the first 5-week period, and by 15.8% of I150/A10-treated patients and 17.0% of A10-treated patients during the second 5-week period. Two serious adverse events were reported with the fixed-dose combination; both patients recovered.


      Data from this adult population with essential hypertension suggest greater efficacy with the fixed-dose combination I150/A5 over A5 monotherapy in lowering SBP after 5 weeks. Both treatment regimens were well tolerated throughout the study. identifier: NCT00956644.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mancia G.
        • De Backer G.
        • Dominiczak A.
        • et al.
        2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        J Hypertens. 2007; 25: 1105-1187
        • Turnbull F.
        • Blood Pressure Lowering Treatment Trialists' Collaboration
        Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
        Lancet. 2003; 362: 1527-1535
        • UK Prospective Diabetes Study Group
        Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
        BMJ. 1998; 317: 703-713
        • Wang J.G.
        • Staessen J.A.
        • Franklin S.S.
        • et al.
        Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome.
        Hypertension. 2005; 45: 907-913
        • Law M.R.
        • Morris J.K.
        • Wald N.J.
        Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
        BMJ. 2009; 338: b1665
        • Sica D.A.
        Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.
        Drugs. 2002; 62: 443-462
        • Weber M.A.
        Creating a combination antihypertensive regimen: what does the research show?.
        J Clin Hypertens. 2003; 5: 12-20
        • Morgan T.
        • Anderson A.
        A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension.
        Am J Hypertens. 2002; 15: 544-549
        • Allemann Y.
        • Fraile B.
        • Lambert M.
        • et al.
        Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
        J Clin Hypertens. 2008; 10: 185-194
        • Chrysant S.G.
        • Melino M.
        • Karki S.
        • et al.
        The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
        Clin Ther. 2008; 30: 587-604
        • NICE
        Hypertension: the clinical management of primary hypertension in adults.
        National Clinical Guideline Centre. August 2011;
        • Fogari R.
        • Zoppi A.
        • Derosa G.
        • et al.
        Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
        J Hum Hypertens. 2007; 21: 220-224
        • Croom K.F.
        • Curran M.P.
        • Goa K.L.
        • Perry C.M.
        Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
        Drugs. 2004; 64: 999-1028
        • Haria M.
        • Wagstaff A.J.
        Drugs. 1995; 50: 560-586
        • Epstein B.J.
        • Vogel K.
        • Palmer B.F.
        Dihydropyridine calcium channel antagonists in the management of hypertension.
        Drugs. 2007; 67: 1309-1327
        • Cockroft D.W.
        • Gault M.H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • O'Brien E.
        • Pickering T.
        • Asmar R.
        • et al.
        Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults.
        Blood Press Monit. 2002; 7: 3-17
        • Smith T.R.
        • Philipp T.
        • Vaisse B.
        Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
        J Clin Hypertens. 2007; 9: 355-364
        • Philipp T.
        • Smith T.R.
        • Glazer R.
        Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
        Clin Ther. 2007; 29: 563-580
        • Flack J.M.
        • Calhoun D.A.
        • Satlin L.
        • et al.
        Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.
        J Hum Hypertens. 2009; 23: 479-489
        • Fogari R.
        • Zoppi A.
        • Mugellini A.
        • et al.
        Efficacy and safety of two treatment combinations of hypertension in very elderly patients.
        Arch Gerontol Geriatr. 2009; 48: 401-405
        • Calhoun D.A.
        • Lacourcière Y.
        • Chiang Y.T.
        • Glazer R.D.
        Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
        Hypertension. 2009; 54: 32-39
        • Oparil S.
        • Giles T.
        • Ofili E.O.
        • et al.
        Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
        J Hypertens. 2011; 29: 161-170
        • Wald D.S.
        • Law M.
        • Morris J.K.
        • et al.
        Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
        Am J Med. 2009; 122: 290-300
        • Pimenta E.
        • Oparil S.
        Fixed combinations in the management of hypertension: patients perspectives and rationale for development and utility of the olmesartan-amlodipine combination.
        Vasc Health Risk Manag. 2008; 4: 653-664